Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex™, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The Zerenex Phase 3 registration program, which is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA), is comprised of an already successfully-completed Phase 3 short-term study, and this ongoing Phase 3 long-term study.    

This Phase 3 long-term study is a multicenter, randomized, open-label, safety and efficacy clinical trial in over 400 ESRD patients on hemodialysis or peritoneal dialysis. The study consists of a 2-week washout period followed by a 52-week safety assessment in which patients are randomized 2:1 to receive either Zerenex or an active control. The 52-week safety assessment period is followed by a 4-week efficacy assessment.  During the 4-week efficacy assessment, only those patients randomized to treatment with Zerenex during the safety assessment period will be randomized in a 1:1 ratio to either continue treatment with Zerenex or to be switched to placebo for a 4-week period.

Dr. Julia Lewis, Professor of Medicine, Department of Nephrology, Vanderbilt University School of Medicine, and member of the Executive Committee of the Collaborative Study Group, is the Study Chair of the Zerenex Phase 3 registration program. Dr. Samuel S. Blumenthal, Professor of Medicine at Medical College of Wisconsin, is the study's Co-Principal Investigator.

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are pleased to have completed patient enrollment into the Zerenex Phase 3 long
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
5. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
6. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
7. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
9. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
10. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
11. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
(Date:5/23/2013)... 2013 Pusan National University Yangsan Hospital, ... and contract research company focused on research and ... today a publication reporting the induction of functional ... and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). ... the May 15 th , 2013 issue of ...
(Date:5/23/2013)... 2013 Watlow®, an industry leader ... systems, recently introduced its new catalog, Watlow® Heating ... in designing and manufacturing industrial heaters, Watlow provides ... serve diverse customer needs. , A description of ... beginning of the book. These options allow high ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 iLuv Creative ... of accessories for the mobile lifestyle, announces they are ... protect, and manage multiple iPad devices efficiently. Winner of ... the 2012 Good Design award, MultiCharger-X is revolutionizing the ... wherever it is deployed. , MultiCharger-X (iAD910) ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3
... , MONROVIA, Calif., June 11 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... Epiphany Injector System for use with the Affinity(TM) Collamer(R) ... of the Epiphany will usher in a new era ...
... COLLEGEVILLE, Pa., June 11 New data from ... that Wyeth,s (NYSE: WYE ) investigational pneumococcal vaccine, ... potential to provide coverage against the 13 most prevalent serotypes ... death in children younger than five worldwide. , ...
... HONG KONG, June 11 /PRNewswire-Asia/ -- With ... week, Filligent, the Australian-led biotech company,is mobilizing stocks of ... A (H1N1) across Australia. The BioMask is the first ... seconds of contact while retaining,the breathability required by front-line ...
Cached Biology Technology:STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 2Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 3Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 4
(Date:5/23/2013)... wrapping of genomic DNA around nucleosomes in the ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich now ... be locally displaced from nucleosomes for transcription. , ... in the cell nucleus, wrapped around disk-shaped particles ... four different histone proteins and accommodating two loops ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. , The project is one of ... engineering at Case Western Reserve and director of ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... In a paper available at the online site of ... of UCLA researchers reports for the first time that ... stimulating production of the antimicrobial protein cathelicidin. The ... active form of vitamin D, leading to production of ...
... basic molecules that make up all living things have ... people are right- or left-handed. This chirality has a ... living organisms. The inception of chirality from the elementary ... mysteries of the origin of life. Scientists at ...
... granted to start the first safety and tolerability trial ... an incurable, paralyzing neurodegenerative disorder that strikes 5 persons ... in the most active period of their lives − ... previously shown the possibilities for the use of VEGF ...
Cached Biology News:Argonne scientists discover possible mechanism for creating 'handedness' in biological molecules 2First trial in patients with a potential treatment of the incurable ALS muscle disease 2First trial in patients with a potential treatment of the incurable ALS muscle disease 3
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: